Related Experiment Videos
Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies
1Cancer Biology Research Laboratory, Stanford University Medical School, Stanford, CA 94305, USA. mbrown@leland.stanford.edu
Abstract:
Human solid tumours are considerably less well oxygenated than normal tissues. This leads to resistance to radiotherapy and anticancer chemotherapy, as well as predisposing to increased tumour metastases. However, tumour hypoxia can be exploited in cancer treatment. One such strategy is to use drugs that are toxic only under hypoxic conditions, and the first drug of this class to enter clinical testing, tirapazamine, is showing considerable promise. The second way to exploit hypoxia is to take advantage of the selective induction of the transcription factor hypoxia-inducible factor 1 (HIF-1) under hypoxic conditions; gene therapy strategies based on this are in development.
Insights
Tumour hypoxia, a condition where solid tumors lack oxygen, presents challenges in cancer treatment but offers unique therapeutic opportunities. Exploiting this, new drugs and gene therapies targeting hypoxic conditions show promise for improved cancer treatment outcomes.
Area of Science:
- Oncology
- Cancer Biology
- Translational Medicine
Background:
- Human solid tumors exhibit significantly lower oxygen levels compared to normal tissues.
- Tumor hypoxia contributes to resistance against radiotherapy and chemotherapy, and promotes metastasis.
- Hypoxia creates a unique tumor microenvironment exploitable for therapeutic strategies.
Purpose of the Study:
- To explore therapeutic strategies that exploit the condition of tumor hypoxia.
- To highlight the potential of hypoxia-activated drugs and gene therapy targeting hypoxia-inducible factor 1 (HIF-1).
Main Methods:
- Review of therapeutic strategies targeting tumor hypoxia.
- Discussion of hypoxia-selective drugs, exemplified by tirapazamine.
- Exploration of gene therapy approaches leveraging hypoxia-inducible factor 1 (HIF-1) induction.
Main Results:
- Tirapazamine, a hypoxia-activated drug, demonstrates promising results in early clinical trials.
- The selective induction of hypoxia-inducible factor 1 (HIF-1) under hypoxic conditions is a viable target.
- Gene therapy strategies based on HIF-1 are under development for cancer treatment.
Conclusions:
- Tumor hypoxia, while a challenge, presents a targetable vulnerability in cancer.
- Hypoxia-activated drugs and HIF-1-based gene therapies represent promising avenues for novel cancer treatments.
- Further research and clinical development are warranted for these hypoxia-targeting strategies.